Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Circulating BRAFV600E Levels Correlate with Treatment in Patients with Thyroid Carcinoma.

Thyroid : official journal of the American Thyroid Association - 1 Mar 2018

Lubitz Carrie C, Zhan Tiannan, Gunda Viswanath, Amin Salma, Gigliotti Benjamin J, Fingeret Abbey L, Holm Tammy M, Wachtel Heather, Sadow Peter M, Wirth Lori J, Sullivan Ryan J, Panka David J, Parangi Sareh

Abstract excerpt

BACKGROUND: BRAFV600E is the most common mutation in papillary thyroid carcinoma (PTC) and can be associated with aggressive disease. Previously, a highly sensitive blood RNA-based BRAFV600E assay was reported. The objective of this study was to assess the correlation of BRAFV600E circulating tumor RNA levels with surgical and medical treatment. METHODS: Circulating BRAFV600E levels were assessed in (i) a murine...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Disease Models, Animal

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Proto-Oncogene Proteins B-raf

Share to Thyroid Carcinoma, Anaplastic

Share to Thyroid Neoplasms

Share to Thyroidectomy

Source

Open in PubMed Open full text

Identifiers

PMID: 29378474
DOI: 10.1089/thy.2017.0322
PMCID: PMC5865613

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Circulating BRAFV600E Levels Correlate with Treatment in Patients with Thyroid Carcinoma.PMID 29378474Read ↗

Detection of Circulating BRAF(V600E) in Patients with Papillary Thyroid Carcinoma.Semantic proximity Read ↗

Mutant BRAF(T1799A) can be detected in the blood of papillary thyroid carcinoma patients and correlates with disease status.Semantic proximity Read ↗

Circulating BRAFV600E in the diagnosis and follow-up of differentiated papillary thyroid carcinoma.Semantic proximity Read ↗

Metastasis-associated MCL1 and P16 copy number alterations dictate resistance to vemurafenib in a BRAFV600E patient-derived papillary thyroid carcinoma preclinical model.Semantic proximity Read ↗

BRAF(V600E) mutation and expression of proangiogenic molecular markers in papillary thyroid carcinomas.Semantic proximity Read ↗

Molecular Profiling and Real-world Outcomes of BRAF V600E-Mutated Papillary Thyroid Cancer.Semantic proximity Read ↗

CirculatingBRAFV600E Cell-Free DNA as a Biomarker in the Management of Anaplastic Thyroid CarcinomaSemantic proximity Read ↗

Fibronectin Contributes to a BRAF Inhibitor-driven Invasive Phenotype in Thyroid Cancer through EGR1, Which Can Be Blocked by Inhibition of ERK1/2.Semantic proximity Read ↗

Circulating Tumor DNA Harboring the BRAFV600E Mutation May Predict Poor Outcomes of Primary Papillary Thyroid Cancer Patients.Semantic proximity Read ↗

Analysis of circulating tumor DNA does not improve the clinical management of patients with locally advanced and metastatic papillary thyroid carcinoma.Semantic proximity Read ↗

BRAF is a therapeutic target in aggressive thyroid carcinoma.Semantic proximity Read ↗

BRAF V600E in papillary thyroid carcinoma is associated with increased programmed death ligand 1 expression and suppressive immune cell infiltration.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.